pyrazines has been researched along with ALS - Amyotrophic Lateral Sclerosis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Guo, B; Li, S; Luo, Y; Sun, Y; Wang, F; Wang, Y; Wen, J; Wu, L; Yang, X; Yu, P; Zhang, G; Zhang, Z; Zheng, C | 1 |
| Scott, A | 1 |
| Andrews, JA; Bian, A; Cudkowicz, ME; Hardiman, O; Lee, J; Malik, FI; Meng, L; Shefner, JM; Wolff, AA | 1 |
| Andrews, JA; Cockcroft, BM; Cudkowicz, ME; Hardiman, O; Lee, JH; Malik, FI; Meng, L; Rudnicki, SA; Shefner, JM; Wolff, AA | 1 |
| Felemban, R; François-Moutal, L; Gokhale, V; Khanna, M; Khanna, R; Miranda, VG; Perez-Miller, S; Sayegh, MR; Scott, DD; Zarnescu, DC | 1 |
| Meng, L; Shefner, JM; Wolff, AA | 1 |
| Meng, L; Shefner, JM; Watson, ML; Wolff, AA | 1 |
| Hinken, AC; Hwee, DT; Jasper, JR; Jia, Z; Kennedy, A; Malik, FI; Morgans, DJ; Russell, AJ; Ryans, J | 1 |
| Cedarbaum, JM; Chen, M; Cudkowicz, ME; Hansen, RL; Jones, D; Lee, J; Mahoney, K; Malik, F; Mao, J; Maragakis, N; Russell, AJ; Saikali, K; Shefner, J; Watson, ML; Wolff, AA | 1 |
| Bromberg, MB; Gibson, SB | 1 |
| Mignani, S; Stutzmann, JM; Vuilhorgne, M | 1 |
| Auguet, M; Chabrier, PE; Demerlé-Pallardy, C | 1 |
| Alavijeh, M; Böhme, GA; Boireau, A; Bordier, F; Brealey, C; Briet, D; Canton, T; Debono, MW; Jahn, G; Jimonet, P; Laville, M; Le Guern, S; Mignani, S; Pratt, J; Roberts, S; Roux, M; Stutzmann, JM; Stygall, J; Vuilhorgne, M | 1 |
3 review(s) available for pyrazines and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside.
Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Excitatory Amino Acid Antagonists; Genetic Therapy; Humans; Imidazoles; Immunosuppressive Agents; Pyrazines; Stem Cell Transplantation; Superoxide Dismutase; Superoxide Dismutase-1 | 2012 |
Synthesis and structure-activity relationships of 4,10-dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazine derivatives: highly potent and selective AMPA receptor antagonists with in vivo activity.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Excitatory Amino Acid Antagonists; Gerbillinae; Imidazoles; Neuroprotective Agents; Pyrazines; Rats; Receptors, AMPA; Structure-Activity Relationship | 2004 |
Nitric oxide synthases: targets for therapeutic strategies in neurological diseases.
Topics: Alzheimer Disease; Amidines; Amyotrophic Lateral Sclerosis; Animals; Benzylamines; Brain Injuries; Brain Ischemia; Enzyme Induction; Humans; Huntington Disease; Mice; Mice, Neurologic Mutants; Mice, Transgenic; Nerve Degeneration; Nerve Tissue Proteins; Nervous System Diseases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Organ Specificity; Polymethacrylic Acids; Pyrazines; Thiophenes | 1999 |
5 trial(s) available for pyrazines and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Male; Pyrazines; Severity of Illness Index; Troponin | 2018 |
A phase III trial of
Topics: Adult; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Muscle Strength; Muscle, Skeletal; Pyrazines; Treatment Outcome | 2019 |
The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS.
Topics: Aged; Amyotrophic Lateral Sclerosis; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Muscle Strength; Pyrazines; Recovery of Function; Treatment Outcome | 2013 |
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Muscle Strength; Pyrazines; Treatment Outcome | 2013 |
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Hand Strength; Humans; Imidazoles; Male; Middle Aged; Muscle, Skeletal; Neuroprotective Agents; Pyrazines; Riluzole; Treatment Outcome | 2012 |
5 other study(ies) available for pyrazines and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1α/Nrf2/HO-1 pathway in ALS mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Female; Hand Strength; Heme Oxygenase-1; Humans; Male; Membrane Proteins; Mice; Mice, Transgenic; Muscle, Skeletal; NF-E2-Related Factor 2; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pyrazines; Superoxide Dismutase-1 | 2021 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a
Topics: Amyotrophic Lateral Sclerosis; Animals; Base Sequence; Binding Sites; DNA-Binding Proteins; Drosophila melanogaster; Drosophila Proteins; Locomotion; Molecular Docking Simulation; Neuroprotective Agents; Piperidines; Protein Binding; Protein Domains; Pyrazines; RNA; Small Molecule Libraries | 2019 |
Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Transgenic; Motor Neurons; Muscle Strength; Muscle, Skeletal; Pyrazines; Troponin | 2014 |
RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Disease Progression; Electrophysiology; Electroshock; Excitatory Amino Acid Antagonists; Glutamic Acid; Imidazoles; In Vitro Techniques; Longevity; Mice; Mice, Transgenic; Muscle, Skeletal; Neurons; Patch-Clamp Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Superoxide Dismutase | 2001 |